Hogan Lovells Publications
Administration's infrastructure initiative unveiled Energy Alert
15 February 2018
Michael Szlamkowicz
Partner, New York
Email michael.szlamkowicz@hoganlovells.com
Phone +1 212 918 3222
Fax +1 212 918 3100
Practice groupCorporate
Michael Szlamkowicz takes a business-oriented approach to his work, helping his clients anticipate and solve a wide range of commercial and legal challenges.
Michael focuses his practice on complex corporate and transactional matters and primarily represents private equity and pension fund sponsors and their portfolio companies, especially in connection with leveraged acquisitions, divestitures, joint ventures, minority investments, financings, restructurings, and general corporate matters.
He also has comprehensive experience with both international and domestic transactions, and frequently counsels on a variety of securities law, corporate governance, and strategic matters. His industry experience includes life sciences, energy, media, fashion and branding, entertainment, telecommunications, information technology, retail, automotive, chemical, and financial services.
Michael studied at McGill University and the Université de Montréal.
Education and admissions
Education
Bachelor of Commerce (Finance, Marketing), McGill University
Bachelor of Laws, University of Montreal
J.D., University of Montreal
Bar admissions and qualifications
New York
Quebec
Representative experience
21st Century Fox in its joint venture with Apollo to create a leading global multi-platform content provider, bringing together Endemol and Shine Group.
Actis on its sale of Anthelio Healthcare Solutions to Atos.
Alcon in the acquisition of Transcend Medical, Inc., developer of technologies for the treatment of glaucoma.
Ford on its acquisition of SAIPS, an Israel-based machine learning company.
Google in its acquisition of Lift Labs.
Next Issue Media in connection with a US$50m investment by KKR.
Novartis in its acquisition of Encore Vision, focused on the development of a novel treatment in presbyopia.
Novartis in its US$665m acquisition of Selexys Pharmaceuticals, a developer of therapeutics to treat pain associated with blood/inflammatory disorders like sickle cell disease.
One Rock Capital on its acquisition of Chevron's Hawaii assets.
One Rock Capital on its acquisition of FXI, a leading foam producer.
Pamplona Capital in its acquisition of BBB Industries.
Pamplona Capital in its acquisition of Charter Nex Holdings.
Pfizer on its immuno-oncology research collaboration with Western Oncolytics to investigate novel oncolytic virus technology.
Valeant on the sale of Dendreon Pharmaceuticals, Inc. to the Sanpower Group Co., Ltd for US$820m.
*Matter handled prior to joining Hogan Lovells.
Latest thinking and events
Hogan Lovells Publications
What’s on the menu for private equity funds, sovereign wealth funds, and investment managers
05 September 2017
